Skip to main page content
U.S. flag
See More

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jan;45(1):353-5.
doi: 10.1128/AAC.45.1.353-355.2001.

In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori

I Gustafsson  1 , L Engstrand, O Cars
Affiliations

In vitro pharmacodynamic studies of activities of ketolides HMR 3647 (Telithromycin) and HMR 3004 against extracellular or intracellular Helicobacter pylori

I Gustafsson et al. Antimicrob Agents Chemother. 2001 Jan.

Abstract

The pharmacodynamic properties of the ketolides HMR 3647 (telithromycin) and HMR 3004 were studied against Helicobacter pylori. Both ketolides showed a pronounced concentration-dependent killing, a significant postantibiotic effect, a long postantibiotic sub-MIC effect, and a reduction of intracellular H. pylori.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Concentration-dependent killing with HMR 3647. Bars indicate standard deviations.
FIG. 2
FIG. 2
(a) Concentration curve for HMR 3004. Bars indicate standard deviations. (b) Intracellular H. pylori exposed to 10 times the MIC of HMR 3647. Bars indicate standard deviations.
See this image and copyright information in PMC

References

    1. Boswell F J, Andrews J M, Wise R. Pharmacodynamic properties of HMR 3647, a new ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother. 1998;41:149–153. - PubMed
    1. Craig W A. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1–12. - PubMed
    1. Enroth H, Wreiber K, Rigo R, Risberg D, Uribe A, Engstrand L. In vitro aging of Helicobacter pylori: changes in morphology, intracellular composition and surface properties. Helicobacter. 1999;4:7–16. - PubMed
    1. Evans D G, Evans D J, Jr, Graham D Y. Adherence and internalization of Helicobacter pylori by HEp-2 cells. Gastroenterology. 1992;102:1557–1567. - PubMed
    1. Glupczynski Y, Burette A, Lamy V, Garrino M G. Evolution of H. pylori primary resistance to antimicrobial agents in Belgium between 1995 and 1998. Gut. 1998;43(Suppl. 2):A48.

Publication types